Trending Now
Mustang Bio Inc. (NASDAQ:MBIO) Reports Preliminary Phase 1/2 MB-106 Clinical Study...
Mustang Bio Inc. (NASDAQ:MBIO) has announced preliminary results of its ongoing phase 1/2 MB-106 clinical trial. MB-106 is a CD20-targeted autologous CAR...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
ASH Accepts Kura Oncology Inc.’s (NASDAQ:KURA) Preliminary KOMET-001 Study Data Accepted...
Kura Oncology Inc. (NASDAQ:KURA) has announced the acceptance for oral presentation of an abstract detailing the preliminary data from its ongoing clinical trial, KOMET-001...
MAKE IT MODERN
LATEST REVIEWS
Celsion Corporation (NASDAQ:CLSN) Unveils An Update On Its Phase I/II OVATION...
Celsion Corporation (NASDAQ:CLSN) has been focusing on its Phase I/II OVATION 2 Study that involved GEN-1 in patients struggling with advanced ovarian cancer. The...
MAKE IT MODERN
PERFORMANCE TRAINING
Black Diamond Therapeutics Inc (NASDAQ:BDTX) Surges on Market Optimism
In the rapidly evolving landscape of healthcare and medicine, precision oncology stands out as a beacon of hope for individuals diagnosed...
XORTX Therapeutics Inc ($XRTX): Pioneering New Treatments for Kidney Disease with a Precision-Medicine Approach
Today, XORTX Therapeutics Inc. (NASDAQ: XRTX) experienced a remarkable surge in its stock price, closing at $2.18 USD—a stunning 86.44% increase. The...
Gritstone Oncology Inc (NASDAQ:GRTS) Begins Phase 1 Clinical Study Of COVID-19 Vaccine By Dosing...
Gritstone Oncology Inc (NASDAQ:GRTS) commenced the phase 1 clinical trial of its COVID-1 vaccine under Gritstone’s “CORAL” program by dosing the first person.
The company will...
AVEO Oncology (NASDAQ:AVEO) Receives FDA Approval For FOTIVDA In Treating Relapsed/Refractory RCC
AVEO Oncology (NASDAQ:AVEO) has announced that the US FDA has approved FOTIVDA® (tivozanib) for treating refractory/relapsed advanced renal cell carcinoma adults that have previously...
Oncoyte Corporation (NASDAQ: OCX) Enters Development And Co-Marketing Collaboration With Thermo Fisher Scientific
Oncoyte Corporation (NASDAQ: OCX) has signed a development and co-marketing collaboration deal for two distributed in vitro diagnostic assays in Thermo Fisher Scientific’s Ion...
MAKE IT MODERN
